Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

Lipids in Health and Disease

Nariman Moradi¹  Soraya Shahrzad²  Abbas Bakhti Arani²  Fatima Zahraa Fouani³  Akram Vatannejad⁴  Reza Fadaei⁵ 

[1] Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;Department of Cardiology, Dr Shariatee training and research Hospital, Tehran University of Medical Sciences, Tehran, Iran;Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran;Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran;Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;

关键词: Coronary artery disease;    Asprosin;    Insulin resistance;    Dyslipidemia;    Adipokine;   

DOI  :  10.1186/s12944-021-01514-9

来源: Springer

【 摘 要 】

BackgroundCoronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD.MethodsIn this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits.Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p <  0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p <  0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI).ConclusionsThe present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.

【 授权许可】

CC BY